MedTrace Logo

Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer

NCT02749136 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2019-11-25

No results posted yet for this study

Summary

The purpose of this study is to assess the feasibility and efficacy outcomes of neoadjuvant modified FOLFIRINOX and postoperative gemcitabine in patients with borderline resectable pancreatic cancer.

Conditions

  • Pancreatic Adenocarcinoma

Interventions

DRUG

Preoperative modified FOLFIRINOX and postoperative gemcitabine

* Preoperative mFOLFIRINOX, every 2 weeks, 8 cycles * Oxaliplatin IV 85 mg/m2 Day (D) 1 * Irinotecan IV 180 mg/m2 D1 * 5-FU continuous IV infusion 2,400 mg/m2 over 46 hours D1-2 * Leucovorin IV 400 mg/m2 D1 * Postoperative gemcitabine, every 4 weeks, 3-6 cycles - Gemcitabine 1,000 mg/ m2 D1, 8, and 15

Sponsors & Collaborators

  • Asan Medical Center

    lead OTHER

Principal Investigators

  • Baek-Yeol Ryoo, MD, PhD · Asan Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2019-09-30
Completion
2019-11-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02749136 on ClinicalTrials.gov